RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 2/Phase 3

Registered title, quoted from ClinicalTrials.gov

A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 26 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 26

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAnhui Provincial Cancer Hospital安徽省肿瘤医院HefeiHospital page
  2. Study siteAnyang Tumor Hospital安阳市肿瘤医院AnyangHospital page
  3. Study siteCancer Hospital CAMS – Shenzhen中国医学科学院肿瘤医院深圳医院ShenzhenHospital page
  4. Study siteFirst Affiliated Hospital of Bengbu Medical University蚌埠医学院第一附属医院BengbuHospital page
  5. Study siteFirst Affiliated Hospital of Chongqing Medical University重庆医科大学附属第一医院ChongqingHospital page
  6. Study siteFirst Affiliated Hospital of Henan University of Science and Technology河南科技大学第一附属医院LuoyangHospital page
  7. Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
  8. Study siteFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page
  9. Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
  10. Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
  11. Study siteFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page
  12. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
  13. Study siteFujian Medical University Union Hospital福建医科大学附属协和医院FuzhouHospital page
  14. Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
  15. Study siteHainan General Hospital / Hainan Medical University hospitals海南医学院附属医院/海南省人民医院HaikouHospital page
  16. Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
  17. Study siteHenan Provincial People's Hospital河南省人民医院ZhengzhouHospital page
  18. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  19. Study siteSecond Xiangya Hospital中南大学湘雅二医院ChangshaHospital page
  20. Study siteShaanxi Provincial People's Hospital陕西省人民医院Xi'anHospital page
  21. Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
  22. Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
  23. Study siteSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page
  24. Study siteSun Yat-sen Memorial Hospital中山大学孙逸仙纪念医院GuangzhouHospital page
  25. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  26. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06891833, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 75 years; sex: women only

    Registered eligibility fields

  2. Patients with HER2-positive invasive breast cancer confirmed by histological examination;

    Inclusion criterion 4

  3. Clinical stage II-III confirmed based on the 8th edition of the American Joint Committee on Cancer (AJCC) staging system before neoadjuvant therapy;

    Inclusion criterion 5

  4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;

    Inclusion criterion 8

  5. Diagnosis of other primary malignancies within 5 years before the first dose;

    Exclusion criterion 2

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06891833, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntarily sign the informed consent form and comply with protocol requirements;
  • Female aged ≥18 and ≤75 years at the time of signing the informed consent form;
  • Expected survival time ≥6 months;
  • Patients with HER2-positive invasive breast cancer confirmed by histological examination;
  • Clinical stage II-III confirmed based on the 8th edition of the American Joint Committee on Cancer (AJCC) staging system before neoadjuvant therapy;
  • Treatment-naive trial participants who have not received any anti-tumor therapy for breast cancer;
  • Trial participants agree to undergo mastectomy or breast-conserving surgery after completion of neoadjuvant therapy;
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
  • Organ function levels must meet the requirements;
  • For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before starting treatment; serum pregnancy must be negative, and the patient must be non-lactating; all enrolled patients should adopt adequate highly effective contraceptive measures throughout the entire treatment cycle and for 7 months after treatment completion.

Exclusion Criteria:

  • History of breast cancer and tumor treatment;
  • Diagnosis of other primary malignancies within 5 years before the first dose;
  • History of severe cardiovascular or cerebrovascular disease within 6 months before screening;
  • Prolonged QTc interval, complete left bundle branch block, third-degree atrioventricular block, or frequent and uncontrolled arrhythmias;
  • Hypertension inadequately controlled with two antihypertensive medications;
  • Concurrent pulmonary disease resulting in severe impairment of pulmonary function;
  • History of interstitial lung disease/interstitial pneumonia requiring steroid therapy, etc.;
  • Unstable thrombotic events requiring therapeutic intervention within 6 months before screening;
  • Positive human immunodeficiency virus antibody, active hepatitis B virus infection, or hepatitis C virus infection;
  • Patients with poorly controlled blood glucose;
  • Severe infection within 4 weeks before the first use of the study drug; active pulmonary inflammation at screening;
  • Receiving systemic corticosteroid therapy at >10 mg/day prednisone or equivalent anti-inflammatory activity, or any form of immunosuppressive therapy, within 2 weeks before the first dose;
  • Known hypersensitivity to the study treatment or any study drug excipients or other monoclonal antibodies;
  • Patients unsuitable for receiving the investigational drug;
  • History of autologous or allogeneic stem cell transplantation or organ transplantation;
  • Severe neurological or psychiatric disorders;
  • Subjects with clinically significant bleeding or a significant bleeding tendency within 4 weeks before signing informed consent;
  • Intestinal obstruction, Crohn's disease, ulcerative colitis, or chronic diarrhea, etc.;
  • Subjects planning to receive, or having received, live vaccines within 28 days before the first dose;
  • Presence of other severe physical or laboratory abnormalities or poor compliance, etc., which may increase the risk of participating in the study or interfere with study results, or patients deemed unsuitable for participation in this study by the investigator.

Quoted from ClinicalTrials.gov, NCT06891833, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06891833, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06891833